Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Summit Therapeutics Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 42 | 57 | +15 |
| Shares | 3.18M | 8.10M | +4.92M (+155.0%) |
| Value | $3.78M | $34.5M | +$30.8M (+814.3%) |
New holders (23)
Institutions that held Summit Therapeutics Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (8)
Institutions that held Summit Therapeutics Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Millennium Management LLC | 431,560 | $514.0K |
| Bank of Montreal | 28,500 | $35.0K |
| Cowen and Company, LLC | 17,249 | $21.0K |
| Two Sigma Securities, LLC | 17,092 | $20.0K |
| Qube Research & Technologies Ltd | 17,120 | $20.0K |
| Bender Robert & Associates | 14,059 | $17.0K |
| Evoke Wealth, LLC | 8,000 | $10.0K |
| BNP Paribas Arbitrage, SA | 1,159 | $1.38K |